George L. Bakris
Springer US
2012e druk, 2014
9781489998118
The Kidney in Heart Failure
Specificaties
Paperback, 250 blz.
|
Engels
Springer US |
2012e druk, 2014
ISBN13: 9781489998118
Rubricering
Verwachte levertijd ongeveer 9 werkdagen
Samenvatting
Chronic Kidney Disease (CKD) is a recognized risk factor for cardiovascular events and death. The coexistence of CKD and heart failure is increasing in prevalence worldwide and requires a unique and subtle approach to patient management.
The Kidney in Heart Failure focuses on the changes that occur in kidney physiology as a function of a failing heart. This comprehensive resource covers epidemiology, pathophysiology, management of kidney disorders and advances in nephropathy management. In addition, the latest therapies, common heart failure dilemmas and kidney disease markers are included. Each chapter is co-authored by a Nephrologist and Cardiologist, offering a unified perspective to these chronic conditions.
This indispensible volume provides the reader with the depth-of-knowledge needed for assessing and treating the cardio renal patient.
Specificaties
ISBN13:9781489998118
Taal:Engels
Bindwijze:paperback
Aantal pagina's:250
Uitgever:Springer US
Druk:2012
Inhoudsopgave
Foreword Peter A. McCulloughPrefacePart One Epidemiology<p>Chapter 1 Epidemiology of Chronic Kidney Disease in Heart Failure</p><p> Ruth C. Campbell and Ali Ahmed </p><p>Chapter 2 Anemia and Cardiovascular Risk in the Kidney Disease Patients: </p><p> What is the best way to achieve and what is the desired hemoglobin?</p><p> Tejas V. Patel and Ajay K. Singh</p> Part Two PathophysiologyChapter 3 Renal Hemodynamic Changes in Heart Failure<p> Ivana Lazich and George L. Bakris</p>Chapter 4 Changes in Kidney Function Following Heart Failure Treatment: Focus on RAS Blockade<p> Mohammed Shakaib and George L. Bakris</p><p>Chapter 5 Extracellular Fluid Volume in the Hypoalbuminemic Diabetic Patient</p><p> Biff F. Palmer</p><p>Chapter 6 B-Type Natriuretic Peptide: Beyond Diagnostic Applications</p><p> Ivan D. Hanson and Peter A. McCullough</p><p> </p>Part Three Management of Kidney Associated Clinical Problems<p>Chapter 7 Hyperkalemia Risk and Treatment of Heart Failure</p><p> Julian Segura and Luis M. Ruilope</p><p>Chapter 8 Management of Heart Failure with Renal Artery Ischaemia</p><p> Andrew K. Roy and Patrick Murray</p><p>Chapter 9 Renal Consequences of Prostaglandin Inhibition in Heart Failure</p><p> Eric M. Brown, Daniel J. Salzberg, Matthew R. Weir</p>Chapter 10 Edema Mechanisms in the Heart Failure Patient and Treatment Options<p> Domenic A. Sica</p><p>Chapter 11 Ultrafiltration and Heart Failure</p><p> Paul Chacko, Donald Kikta Jr., William T. Abraham</p><p> </p>Part Four Advances in Nephropathy Management: Influences on CVD Risk<p>Chapter 12 Combination Therapy in Hypertension Treatment</p><p> Raymond V. Oliva and George L. Bakris</p><p>Chapter 13 Medication Adherence in Heart Failure</p><p> Daniel E. Hilleman and Jennifer A. Campbell</p><p>Chapter 14 New Markers of Vascular Risk</p><p> David Davidson and Michael H. Davidson</p><p>Chapter 15 Dietary Paradoxes to Optimize CV Risk Management in CKD</p><p> Raghu V. Durvasula and Katherine R. Tuttle</p>PrefacePart One Epidemiology<p>Chapter 1 Epidemiology of Chronic Kidney Disease in Heart Failure</p><p> Ruth C. Campbell and Ali Ahmed </p><p>Chapter 2 Anemia and Cardiovascular Risk in the Kidney Disease Patients: </p><p> What is the best way to achieve and what is the desired hemoglobin?</p><p> Tejas V. Patel and Ajay K. Singh</p> Part Two PathophysiologyChapter 3 Renal Hemodynamic Changes in Heart Failure<p> Ivana Lazich and George L. Bakris</p>Chapter 4 Changes in Kidney Function Following Heart Failure Treatment: Focus on RAS Blockade<p> Mohammed Shakaib and George L. Bakris</p><p>Chapter 5 Extracellular Fluid Volume in the Hypoalbuminemic Diabetic Patient</p><p> Biff F. Palmer</p><p>Chapter 6 B-Type Natriuretic Peptide: Beyond Diagnostic Applications</p><p> Ivan D. Hanson and Peter A. McCullough</p><p> </p>Part Three Management of Kidney Associated Clinical Problems<p>Chapter 7 Hyperkalemia Risk and Treatment of Heart Failure</p><p> Julian Segura and Luis M. Ruilope</p><p>Chapter 8 Management of Heart Failure with Renal Artery Ischaemia</p><p> Andrew K. Roy and Patrick Murray</p><p>Chapter 9 Renal Consequences of Prostaglandin Inhibition in Heart Failure</p><p> Eric M. Brown, Daniel J. Salzberg, Matthew R. Weir</p>Chapter 10 Edema Mechanisms in the Heart Failure Patient and Treatment Options<p> Domenic A. Sica</p><p>Chapter 11 Ultrafiltration and Heart Failure</p><p> Paul Chacko, Donald Kikta Jr., William T. Abraham</p><p> </p>Part Four Advances in Nephropathy Management: Influences on CVD Risk<p>Chapter 12 Combination Therapy in Hypertension Treatment</p><p> Raymond V. Oliva and George L. Bakris</p><p>Chapter 13 Medication Adherence in Heart Failure</p><p> Daniel E. Hilleman and Jennifer A. Campbell</p><p>Chapter 14 New Markers of Vascular Risk</p><p> David Davidson and Michael H. Davidson</p><p>Chapter 15 Dietary Paradoxes to Optimize CV Risk Management in CKD</p><p> Raghu V. Durvasula and Katherine R. Tuttle</p><p> Ivana Lazich and George L. Bakris</p>Chapter 4 Changes in Kidney Function Following Heart Failure Treatment: Focus on RAS Blockade<p> Mohammed Shakaib and George L. Bakris</p><p>Chapter 5 Extracellular Fluid Volume in the Hypoalbuminemic Diabetic Patient</p><p> Biff F. Palmer</p><p>Chapter 6 B-Type Natriuretic Peptide: Beyond Diagnostic Applications</p><p> Ivan D. Hanson and Peter A. McCullough</p><p> </p>Part Three Management of Kidney Associated Clinical Problems<p>Chapter 7 Hyperkalemia Risk and Treatment of Heart Failure</p><p> Julian Segura and Luis M. Ruilope</p><p>Chapter 8 Management of Heart Failure with Renal Artery Ischaemia</p><p> Andrew K. Roy and Patrick Murray</p><p>Chapter 9 Renal Consequences of Prostaglandin Inhibition in Heart Failure</p><p> Eric M. Brown, Daniel J. Salzberg, Matthew R. Weir</p>Chapter 10 Edema Mechanisms in the Heart Failure Patient and Treatment Options<p> Domenic A. Sica</p><p>Chapter 11 Ultrafiltration and Heart Failure</p><p> Paul Chacko, Donald Kikta Jr., William T. Abraham</p><p> </p>Part Four Advances in Nephropathy Management: Influences on CVD Risk<p>Chapter 12 Combination Therapy in Hypertension Treatment</p><p> Raymond V. Oliva and George L. Bakris</p><p>Chapter 13 Medication Adherence in Heart Failure</p><p> Daniel E. Hilleman and Jennifer A. Campbell</p><p>Chapter 14 New Markers of Vascular Risk</p><p> David Davidson and Michael H. Davidson</p><p>Chapter 15 Dietary Paradoxes to Optimize CV Risk Management in CKD</p><p> Raghu V. Durvasula and Katherine R. Tuttle</p><p> Mohammed Shakaib and George L. Bakris</p><p>Chapter 5 Extracellular Fluid Volume in the Hypoalbuminemic Diabetic Patient</p><p> Biff F. Palmer</p><p>Chapter 6 B-Type Natriuretic Peptide: Beyond Diagnostic Applications</p><p> Ivan D. Hanson and Peter A. McCullough</p><p> </p>Part Three Management of Kidney Associated Clinical Problems<p>Chapter 7 Hyperkalemia Risk and Treatment of Heart Failure</p><p> Julian Segura and Luis M. Ruilope</p><p>Chapter 8 Management of Heart Failure with Renal Artery Ischaemia</p><p> Andrew K. Roy and Patrick Murray</p><p>Chapter 9 Renal Consequences of Prostaglandin Inhibition in Heart Failure</p><p> Eric M. Brown, Daniel J. Salzberg, Matthew R. Weir</p>Chapter 10 Edema Mechanisms in the Heart Failure Patient and Treatment Options<p> Domenic A. Sica</p><p>Chapter 11 Ultrafiltration and Heart Failure</p><p> Paul Chacko, Donald Kikta Jr., William T. Abraham</p><p> </p>Part Four Advances in Nephropathy Management: Influences on CVD Risk<p>Chapter 12 Combination Therapy in Hypertension Treatment</p><p> Raymond V. Oliva and George L. Bakris</p><p>Chapter 13 Medication Adherence in Heart Failure</p><p> Daniel E. Hilleman and Jennifer A. Campbell</p><p>Chapter 14 New Markers of Vascular Risk</p><p> David Davidson and Michael H. Davidson</p><p>Chapter 15 Dietary Paradoxes to Optimize CV Risk Management in CKD</p><p> Raghu V. Durvasula and Katherine R. Tuttle</p>